Cytori Therapeutics

Health biotech drug development healthtech life sciences medical devices medtech oncology pharma therapy

Cytori Therapeutics develops cellular therapeutics for specific diseases and medical conditions. The Company primarily provides Cytori Cell Therapy for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets, and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The Company also provides a number of products for use in treating various cancers.

Market capitalization(2018-04-23)

$9.3 M

Type

Public

San Diego, US

Founded

2002

Size (employees)

80 (est)

Website

cytori.com

Cytori Therapeutics was founded in 2002 and is headquartered in San Diego, US

Report incorrect company information

Cytori Therapeutics Office Locations

Cytori Therapeutics has offices in Deeside, San Antonio, San Diego and Tokyo

San Diego, US (HQ)

3020 Callan Road

San Antonio, US

12500 Network Blvd

Tokyo, JP

Otemachi Park Building 7F 1-1-1 Otemachi, Chiyoda-ku

Deeside, GB

Deeside Industrial Park East Unit 68, Third Avenue

Show all (4)

Report incorrect company information

Cytori Therapeutics Financials and Metrics

Cytori Therapeutics Financials

Cytori Therapeutics's revenue was reported to be $4.66 m in FY, 2016 which is a 3.8% decrease from the previous period.

Summary

USD
Net income (FY, 2017)	(22.7 m)
EBIT (FY, 2017)	(20.7 m)
Market capitalization (23-Apr-2018)	9.3 m
Cash (31-Dec-2017)	9.6 m

Cytori Therapeutics's current market capitalization is $9.3 m.

Income Statement

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	7.1 m	5 m	4.8 m	4.7 m
Revenue growth, %		(30%)	(2%)	(4%)
Cost of goods sold	3.4 m	2.9 m	3.2 m	2.7 m
Gross profit	3.7 m	2 m	1.7 m	1.9 m

show all

Balance Sheet

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	15.5 m	14.6 m	14.3 m	12.6 m	9.6 m
Accounts Receivable
Inventories				3.7 m	3.2 m
Current Assets	24.6 m	21.7 m	21.2 m	18.7 m	14.9 m

show all

Cash Flow

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(26.2 m)	(37.4 m)	(18.7 m)	(22 m)	(22.7 m)
Depreciation and Amortization	1.6 m	779 k	1.1 m	1.2 m	2.2 m
Inventories	(459 k)	(815 k)	490 k	471 k	251 k
Accounts Payable	(409 k)	(1.1 m)	1 m	(673 k)	(1.8 m)